Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1959 1
1962 1
1964 1
1965 1
1966 1
1967 1
1968 1
1969 1
1972 1
1974 1
1975 1
1977 1
1979 1
1980 4
1981 1
1982 3
1983 1
1984 2
1985 6
1986 4
1987 2
1988 1
1989 1
1990 3
1991 4
1992 3
1993 3
1994 4
1995 2
1996 1
1997 1
1998 1
1999 1
2000 2
2001 8
2002 5
2003 6
2004 6
2005 6
2006 8
2007 6
2008 7
2009 15
2010 7
2011 4
2012 7
2013 8
2014 16
2015 10
2016 8
2017 15
2018 12
2019 19
2020 19
2021 22
2022 10
2023 7
2024 12
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, D'Arcy S, Delpuech O, DuPont M, Fisher DI, Gangl ET, Lewis H, Trueman D, Wali N, Williamson SC, Moss J, Montaudon E, Derrien H, Marangoni E, Miragaia RJ, Gagrica S, Morentin-Gutierrez P, Moss TA, Maglennon G, Sutton D, Polanski R, Rosen A, Cairns J, Zhang P, Sánchez-Guixé M, Serra V, Critchlow SE, Scott JS, Lindemann JPO, Barry ST, Klinowska T, Morrow CJ, Carnevalli LS. Lawson M, et al. Among authors: lindemann jpo. Cancer Res. 2023 Dec 1;83(23):3989-4004. doi: 10.1158/0008-5472.CAN-23-0694. Cancer Res. 2023. PMID: 37725704 Free PMC article.
AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. Hyman DM, et al. Among authors: lindemann jpo. J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. J Clin Oncol. 2017. PMID: 28489509 Free PMC article.
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Ajimi M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, van Zyl R, Arkania E. Oliveira M, et al. Among authors: lindemann jpo. Lancet Oncol. 2024 Nov;25(11):1424-1439. doi: 10.1016/S1470-2045(24)00387-5. Lancet Oncol. 2024. PMID: 39481395 Clinical Trial.
[Traumatology of the nose].
Engelhardt D, Sommer F, Lindemann J, Theodoraki MN, Scheithauer M. Engelhardt D, et al. Among authors: lindemann j. HNO. 2022 Oct;70(10):751-755. doi: 10.1007/s00106-022-01220-7. Epub 2022 Sep 21. HNO. 2022. PMID: 36129487 Review. German.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. Among authors: lindemann jp. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. Hamilton E, et al. Among authors: lindemann jpo. Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8. Ann Oncol. 2024. PMID: 38729567 Free article. Clinical Trial.
[Nasal turbinate surgery].
Sommer F, Lindemann J, Scheithauer MO, Hoffmann TK, Veit JA. Sommer F, et al. Among authors: lindemann j. HNO. 2017 May;65(5):443-456. doi: 10.1007/s00106-017-0349-5. HNO. 2017. PMID: 28401248 Review. German.
[Pregnancy Rhinitis - an Update].
Friebe-Hoffmann U, Lindemann J. Friebe-Hoffmann U, et al. Among authors: lindemann j. Z Geburtshilfe Neonatol. 2017 Apr;221(2):59-66. doi: 10.1055/s-0042-110325. Epub 2016 Jul 27. Z Geburtshilfe Neonatol. 2017. PMID: 28561209 Review. German.
294 results